68 Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy

Archive ouverte

Bouziotis, Penelope | Stellas, Dimitris | Thomas, Eloise | Truillet, Charles | Tsoukalas, Charalampos | Lux, François | Tsotakos, Theodoros | Xanthopoulos, Stavros | Paravatou-Petsotas, Maria | Gaitanis, Anastasios | Moulopoulos, Lia Angela | Koutoulidis, Vassilis | Anagnostopoulos, Constantinos | Tillement, Olivier

Edité par CCSD ; Future Medicine -

International audience. Aim: The aim of this study was to develop a dual-modality positron emission tomography/magnetic resonance (PET/MR) imaging probe by radiolabeling gadolinium-containing AGuIX derivatives with the positron-emitter Gallium-68 (68Ga). Materials & methods: AGuIX@NODAGA nanoparticles were labeled with 68Ga at high efficiency. Tumor accumulation in an appropriate disease model was assessed by ex vivo biodistribution and in vivo PET/MR imaging. Results: 68Ga-AGuIX@NODAGA was proven to passively accumulate in U87MG human glioblastoma tumor xenografts. Metabolite assessment in serum, urine and tumor samples showed that 68Ga-AGuIX@NODAGA remains unmetabolized up to at least 60 min postinjection. Conclusion: This study demonstrates that 68Ga-AGuIX@NODAGA can be used as a dual-modality PET/MR imaging agent with passive accumulation in the diseased area, thus showing great potential for PET/MR image-guided radiation therapy.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion